Julian G Hurdle

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 19

Top Topics

Clostridium Difficile

Methicillin Resistant Staphylococcus Aureus

Top Venues

Antimicrobial agents and chemotherapy

ACS infectious diseases

Microbiology spectrum

ACS chemical biology

This page only lists publications with an associated author ORCID identifier.

Publications

Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Chetna Dureja, Jacob T Rutherford, Fahad B A Pavel, Krissada Norseeda, Isaac Prah, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. Antimicrobial agents and chemotherapy 68 (3) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases 10 (5) (2024)
Chetna Dureja, Jacob T Rutherford, Fahad B A Pavel, Krissada Norseeda, Isaac Prah, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. Antimicrobial agents and chemotherapy (2024)
Chetna Dureja, Jacob T Rutherford, Fahad B A Pavel, Krissada Norseeda, Isaac Prah, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. Antimicrobial agents and chemotherapy 68 (3) (2024)
Chetna Dureja, Jacob T Rutherford, Fahad B A Pavel, Krissada Norseeda, Isaac Prah, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. Antimicrobial agents and chemotherapy (2024)
Chetna Dureja, Jacob T Rutherford, Fahad B A Pavel, Krissada Norseeda, Isaac Prah, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. Antimicrobial agents and chemotherapy 68 (3) (2024)
Jacob T Rutherford, Kristiana Avad, Chetna Dureja, Krissada Norseeda, Bibek Gc, Chenggang Wu, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
Evaluation of Fusobacterium nucleatum Enoyl-ACP Reductase (FabK) as a Narrow-Spectrum Drug Target. ACS infectious diseases (2024)
Chetna Dureja, Jacob T Rutherford, Fahad B A Pavel, Krissada Norseeda, Isaac Prah, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. Antimicrobial agents and chemotherapy 68 (3) (2024)
Chetna Dureja, Jacob T Rutherford, Fahad B A Pavel, Krissada Norseeda, Isaac Prah, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. Antimicrobial agents and chemotherapy 68 (3) (2024)
Chetna Dureja, Jacob T Rutherford, Fahad B A Pavel, Krissada Norseeda, Isaac Prah, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. Antimicrobial agents and chemotherapy 68 (3) (2024)
Chetna Dureja, Jacob T Rutherford, Fahad B A Pavel, Krissada Norseeda, Isaac Prah, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) Inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy. bioRxiv : the preprint server for biology (2023)
Abiola Olumuyiwa Olaitan, Chetna Dureja, Madison A Youngblom, Madeline A Topf, Wan-Jou Shen, Anne J Gonzales-Luna, Aditi Deshpande, Kirk E Hevener, Jane Freeman, Mark H Wilcox, Kelli L Palmer, Kevin W Garey, Caitlin S Pepperell, Julian G Hurdle
Decoding a cryptic mechanism of metronidazole resistance among globally disseminated fluoroquinolone-resistant Clostridioides difficile. Nature communications 14 (1) (2023)
Ravi K R Marreddy, Abiola O Olaitan, Jordan N May, Min Dong, Julian G Hurdle
Ebselen Not Only Inhibits Clostridioides difficile Toxins but Displays Redox-Associated Cellular Killing. Microbiology spectrum 9 (2) (2021)
Jesse A Jones, Allan M Prior, Ravi K R Marreddy, Rebecca D Wahrmund, Julian G Hurdle, Dianqing Sun, Kirk E Hevener
Small-Molecule Inhibition of the C. difficile FAS-II Enzyme, FabK, Results in Selective Activity. ACS chemical biology 14 (7) (2019)
Ravi K R Marreddy, Xiaoqian Wu, Madhab Sapkota, Allan M Prior, Jesse A Jones, Dianqing Sun, Kirk E Hevener, Julian G Hurdle
The Fatty Acid Synthesis Protein Enoyl-ACP Reductase II (FabK) is a Target for Narrow-Spectrum Antibacterials for Clostridium difficile Infection. ACS infectious diseases 5 (2) (2018)